Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer

Molecular Cancer Therapeutics

Volumn 14, Issue 1, 2015, Pages 141-150

  Sato, Kazuhide ^a   Hanaoka, Hirofumi ^a   Watanabe, Rira ^a   Nakajima, Takahito ^a   Choyke, Peter L ^a   Kobayashi, Hisataka ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IR 700; IR 800; LUCIFERASE; PHOTOSENSITIZING AGENT; PHTHALOCYANINE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; IMMUNOGLOBULIN; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PHTHALOCYANINE; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NEAR INFRARED PHOTOIMMUNOTHERAPY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; IMMUNOTHERAPY; INFRARED RADIATION; NUDE MOUSE; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROCEDURES; RADIATION RESPONSE; THERAPEUTIC USE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; INDOLES; INFRARED RAYS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RADIATION-SENSITIZING AGENTS; TRASTUZUMAB;

EID: 84961291875     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0658     Document Type: Article

References (36)

1. Siegel R. Cancer statistics, 2013. CA cancer J Clin 2013;63:11-30.
2. Ng JS, Low JJ, Ilancheran A. Epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2012;26:337-45.
3. Society MM. Patients with stage iii and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
4. Sudo T. Molecular-targeted therapies for ovarian cancer: prospects for the future. Int J Clin Oncol 2012;17:424-9.
5. Banerjee S, Kaye S. The role of targeted therapy in ovarian cancer. Eur J Cancer 2011;47:S116-30.
6. Mew D, Wat CK, Towers GH, Levy JG. Photoimmunotherapy: treatment of animal tumors with tumor-specific. J Immunol 1983;130:1473-7.
7. Spring BQ, Abu-Yousif AO, Palanisami A, Rizvi I, Zheng X, Mai Z, et al. Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. Proc Natl Acad Sci U S A 2014;111:E933-42.
8. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL. Cancer cell - selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 2011;17:1685-91.
9. Mitsunaga M, Nakajima T. Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy. BMC Cancer 2012;12:1.
10. Mitsunaga M, Nakajima T, Sano K, Choyke PL, Kobayashi H. Near-infrared Theranostic Photoimmunotherapy (PIT): Repeated Exposure of Light Enhances the Effect of Immunoconjugate. Bioconjug Chem 2012;23:604-9.
11. Sato K, Watanabe R, Hanaoka H, Harada T, Nakajima T, Kim I, et al. Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor. Mol Oncol 2014;8:620-32.
12. Nakajima T, Sano K, Mitsunaga M, Choyke PL, Kobayashi H. Real-time monitoring of in vivo acute necrotic cancer cell death induced by near infrared photoimmunotherapy using fluorescence lifetime imaging. Cancer Res 2012;72:4622-8.
13. Sano K, Nakajima T, Choyke PL, Kobayashi H. Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano 2013;7:717-24.
14. Sato K, Watanabe T, Wang S, Kakeno M, Matsuzawa K, Matsui T, et al. Numb controls E-cadherin endocytosis through p120 catenin with aPKC. Mol Biol Cell 2011;22:3103-19.
15. Nakajima T, Sano K, Choyke PL, Kobayashi H. Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics 2013;3:357-65.
16. Gaborit N, Larbouret C, Vallaghe J, Peyrusson F, Bascoul-Mollevi C, Crapez E, et al. Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J Biol Chem 2011;286:11337-45.
17. Dubessy C, Merlin JM, Marchal C, Guillemin F. Spheroids in radiobiology and photodynamic therapy. Crit Rev Oncol Hematol 2000;36:179-92.
18. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 2003;63:1288-96.
19. Smolle E, Taucher V, Haybaeck J. Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer Res 2014;34:1553-61.
20. Morotti M, Becker CM, Menada MV, Ferrero S. Targeting tyrosine-kinases in ovarian cancer. Expert Opin Investig Drugs 2013;22:1265-79.
21. Pliarchopoulou K, Pectasides D. Epithelial ovarian cancer: focus on targeted therapy. Crit Rev Oncol Hematol 2011;79:17-23.
22. Penzvalto Z, Surowiak P, Gyorffy B. Biomarkers for systemic therapy in ovarian cancer. Curr Cancer Drug Targets 2014;14:259-73.
23. Weberpals JI, Koti M, Squire JA. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genet 2011;204:525-35.
24. Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, Barber F, et al. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer 2013;49:3936-44.
25. Hahn SM, Fraker DL, Mick R, Metz J, Busch TM, Smith D, et al. A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res 2006;12:2517-25.
26. Kosaka N, Ogawa M, Paik DS, Paik CH, Choyke PL, Kobayashi H. Semiquantitative assessment of the microdistribution of fluorescence-labeled monoclonal antibody in small peritoneal disseminations of ovarian cancer. Cancer Sci 2010;101:820-5.
27. Contag PR, Olomu IN, Stevenson DK CC. Bioluminescent indicators in living mammals. Nat Med 1998;4:245-7.
28. Dothager RS, Flentie K, Moss B, Pan M-H, Kesarwala A, Piwnica-Worms D. Advances in bioluminescence imaging of live animal models. Curr Opin Biotechnol 2009;20:45-53.
29. Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005;5:796-806.
30. Matsumoto Y, Miwa S, Zhang Y, Hiroshima Y, Yano S, Uehara F, et al. Efficacy of tumor-targeting salmonella typhimurium A1-R on nude mouse models of metastatic and disseminated human ovarian cancer. J Cell Biochem 2014;115:1996-2003.
31. Zamaraeva MV, Sabirov RZ, Maeno E, Ando-Akatsuka Y, Bessonova SV, Okada Y. Cells die with increased cytosolic ATP during apoptosis: a bioluminescence study with intracellular luciferase. Cell Death Differ 2005;12:1390-7.
32. Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE, Contag CH, et al. Rapid and quantitative assessment of cancer treatment response using In Vivo bioluminescence imaging 1 days post sham treatment. Neoplasia 2000;2:491-5.
33. Leist BM, Single B, Castoldi AF, Kühnle S. A switch in the decision between apoptosis and necrosis. J Exp Med 1997;185:1481-6.
34. Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res 2014;74:2907-12.
35. Hiroshima Y, Maawy A, Zhang Y, Sato S, Murakami T, Yamamoto M, et al. Fluorescence-guided surgery in combination with UVC irradiation cures metastatic human pancreatic cancer in orthotopic mouse models. PLoS ONE 2014;9:e99977.
36. Shirasu N, Yamada H, Shibaguchi H, Kuroki M, Kuroki M. Potent and specific antitumor effect of CEA-targeted photoimmunotherapy. Int J Cancer 2014;135:2697-710.